Vitamin C- The Real Story

by Steve Hickey

  42. Speir, E. “Cytomegalovirus Gene Regulation by Reactive Oxygen Species. Agents in Atherosclerosis.” Ann NY Acad Sci 899 (2000): 363–374.

  43. Epstein, S.E., Y.F. Zhou, J. Zhu. “Infection and Atherosclerosis: Emerging Mechanistic Paradigms.” Circulation 100:4 (1999): e20–e28.

  44. Kariuki Njenga, M., and C.A. Dangler. “Endothelial MHC Class II Antigen Expression and Endarteritis Associated with Marek’s Disease Virus Infection in Chickens.” Vet Pathol 32:4 (1995): 403–411.

  45. Fabricant, C.G., J. Fabricant, M.M. Litrenta, et al. “Virus-induced Atherosclerosis.” J Exp Med 148:1 (1978): 335–340. Minick, C.R., C.G. Fabricant, J. Fabricant, et al. “Atheroarteriosclerosis Induced by Infection with a Herpesvirus.” Am J Pathol 96:3 (1979): 673–706. Fabricant, C.G., J. Fabricant, C.R. Minick, et al. “Herpesvirus-induced Atherosclerosis in Chickens.” Fed Proc 42:8 (1983): 2476–2479. Hajjar, D.P., D.J. Falcone, C.G. Fabricant, et al “Altered Cholesteryl Ester Cycle is Associated with Lipid Accumulation in Herpesvirus-infected Arterial Smooth Muscle Cells.” J Biol Chem 260:10 (1985): 6124–6128.

  46. Fabricant, C.G., and J. Fabricant. “Atherosclerosis Induced by Infection with Marek’s Disease Herpesvirus in Chickens.” Am Heart J 138:5 Part 2 (1999): S465-S468.

  47. Shih, J.C., R. Pyrzak, J.S. Guy. “Discovery of Noninfectious Viral Genes Complementary to Marek’s Disease Herpes Virus in Quail Susceptible to Cholesterol-induced Atherosclerosis.” J Nutr 119:2 (1989): 294–298.

  48. Span, A.H., G. Grauls, F. Bosman, et al. “Cytomegalovirus Infection Induces Vascular Injury in the Rat.” Atherosclerosis 93:1–2 (1992): 41–52. Span, A.H., P.M. Frederik, G. Grauls, et al. “CMV-induced Vascular Injury: An Electron-microscopic Study in the Rat.” In Vivo 7:6A (1993): 567–573.

  49. Berencsi, K., V. Endresz, D. Klurfeld, et al. “Early Atherosclerotic Plaques in the Aorta following Cytomegalovirus Infection of Mice.” Cell Adhes Commun 5:1 (1998): 39–47. Hsich, E., Y.F. Zhou, B. Paigen, et al. “Cytomegalovirus Infection Increases Development of Atherosclerosis in Apolipoprotein-E Knockout Mice.” Atherosclerosis 156:1 (2001): 23–28.

  50. Benditt, E.P., T. Barrett, J.K. McDougall. “Viruses in the Etiology of Atherosclerosis.” Proc Natl Acad Sci USA 80:20 (1983): 6386–6389.

  51. Melnick, J.L., E. Adam, M.E. Debakey. “Cytomegalovirus and Atherosclerosis.” Eur Heart J 14:Suppl K (1993): 30–38. Hendrix, M.G., M.M. Salimans, C.P. van Boven, et al. “High Prevalence of Latently Present Cytomegalovirus in Arterial Walls of Patients Suffering from Grade III Atherosclerosis.” Am J Pathol 136:1 (1990): 23–28. Hendrix, M.G., M. Daemen, C.A. Bruggeman. “Cytomegalovirus Nucleic Acid Distribution within the Human Vascular Tree.” Am J Pathol 138:3 (1991): 563–567. Vercellotti, G.M. “Effects of Viral Activation of the Vessel Wall on Inflammation and Thrombosis.” Blood Coagul Fibrinolysis 9:Suppl 2 (1998): S3-S6. Hu, W., J. Liu , S. Niu, et al. “Prevalence of CMV in Arterial Walls and Leukocytes in Patients with Atherosclerosis.” Chin Med J (England) 114:11 (2001): 1208–1210.

  52. Tanaka, S., Y. Toh, R. Mori, et al. “Possible Role of Cytomegalovirus in the Pathogenesis of Inflammatory Aortic Diseases: A Preliminary Report.” J Vasc Surg 16:2 (1992): 274–279. Yonemitsu, Y., K. Komori, K. Sueishi, et al. “Possible Role of Cytomegalovirus Infection in the Pathogenesis of Human Vascular Diseases.” Nippon Rinsho 56:1 (1998): 102–108.

  53. Melnick, J.L., B.L. Petrie, G.R. Dreesman, et al. “Cytomegalovirus Antigen within Human Arterial Smooth Muscle Cells.” Lancet 2:8351 (1983): 644–647. Shih, J.C., and D.W. Kelemen. “Possible Role of Viruses in Atherosclerosis.” Adv Exp Med Biol 369 (1995): 89–98. Nerheim, P.L., J.L. Meier, M.A. Vasef, et al. “Enhanced Cytomegalovirus Infection in Atherosclerotic Human Blood Vessels.” Am J Pathol 164:2 (2004): 589–600.

  54. Melnick, J.L., C. Hu, J. Burek, et al. “Cytomegalovirus DNA in Arterial Walls of Patients with Atherosclerosis.” J Med Virol 42:2 (1994): 170–174.

  55. Hendrix, M.G., P.H. Dormans, P. Kitslaar, et al. “The Presence of Cytomegalovirus Nucleic Acids in Arterial Walls of Atherosclerotic and Nonatherosclerotic Patients.” Am J Pathol 134:5 (1989): 1151–1157.

  56. Biocina, B., I. Husedzinovic, Z. Sutlic, et al. “Cytomegalovirus Disease as a Possible Etiologic Factor for Early Atherosclerosis.” Coll Antropol 23:2 (1999): 673–681.

  57. Pahl, E., F.J. Fricker, J. Armitage, et al. “Coronary Arteriosclerosis in Pediatric Heart Transplant Survivors: Limitation of Long-term Survival.” J Pediatr 116:2 (1990): 177–183.

  58. Yamashiroya, H.M., L. Ghosh, R. Yang, et al. “Herpesviridae in the Coronary Arteries and Aorta of Young Trauma Victims.” Am J Pathol 130:1 (1988): 71–79.

  59. Bruggeman, C.A. “Does Cytomegalovirus Play a Role in Atherosclerosis?” Herpes 7:2 (2000): 51–54. Melnick, J.L., E. Adam, M.E. DeBakey. “Cytomegalovirus and Atherosclerosis.” Bioessays 17:10 (1995): 899–903.

  60. Dhaunsi, G.S., J. Kaur, R.B. Turner. “Role of NADPH Oxidase in Cytomegalovirus-induced Proliferation of Human Coronary Artery Smooth Muscle Cells.” J Biomed Sci 10:5 (2003): 505–509.

  61. Cheng, J.W., and N.G. Rivera. “Infection and Atherosclerosis—Focus on Cytomegalovirus and Chlamydia pneumoniae.” Ann Pharmacother 32:12 (1998): 1310–1316. High, K.P. “Atherosclerosis and Infection Due to Chlamydia pneumoniae or Cytomegalovirus: Weighing the Evidence.” Clin Infect Dis 28:4 (1999): 746–749.

  62. Famularo, G., V. Trinchieri, G. Santini, et al. “Infections, Atherosclerosis, and Coronary Heart Disease.” Ann Ital Med Int 15:2 (2000): 144–155. Fong, I.W. “Emerging Relations between Infectious Diseases and Coronary Artery Disease and Atherosclerosis.” Can Med Assoc J 163:1 (2000): 49–56. Mussa, F.F., H. Chai, X. Wang, et al. “Chlamydia pneumoniae and Vascular Disease: An Update.” J Vasc Surg 43:6 (2006): 1301–1307.

  63. Kuo, C.C., A.M. Gown, E.P. Benditt, et al. “Detection of Chlamydia pneumoniae in Aortic Lesions of Atherosclerosis by Immunocytochemical Stain.” Arterioscler Thromb 13:10 (1993): 1501–1504. Kuo, C.C., J.T. Grayston, L.A. Campbell, et al. “Chlamydia pneumoniae (TWAR) in Coronary Arteries of Young Adults (15–34 Years Old).” Proc Natl Acad Sci USA 92:15 (1995): 6911–6914. Davidson, M., C.C. Kuo, J.P. Middaugh, et al. “Confirmed Previous Infection with Chlamydia pneumoniae (TWAR) and Its Presence in Early Coronary Atherosclerosis.” Circulation 98:7 (1998): 628–633.

  64. Muhlestein, J.B., E.H. Hammond, J.F. Carlquist, et al. “Increased Incidence of Chlamydia Species within the Coronary Arteries of Patients with Symptomatic Atherosclerotic versus Other Forms of Cardiovascular Disease.” J Am Coll Cardiol 27:7 (1996): 1555–1561. Campbell, L.A., et al. “Detection of Chlamydia pneumoniae in Atherectomy Tissue from Patients with Symptomatic Coronary Artery Disease.” In Orfila, J., G. Byrne, M. Chernesky, et al. (eds.). Chlamydial Infections. Bologna, Italy: Societa Editrice Esculapio, 1994, pp. 212–215. Maass, M., J. Gieffers, E. Krause, et al. “Poor Correlation between Microimmunofluorescence Serology and Polymerase Chain Reaction for Detection of Vascular Chlamydia pneumoniae Infection in Coronary Artery Disease Patients.” Med Microbiol Immunol 187 (1998): 103–106.

  65. Espinola-Klein, C., H.J. Rupprecht, S. Blankenberg, et al. “Are Morphological or Functional Changes in the Carotid Artery Wall Associated with Chlamydia pneumoniae, Helicobacter pylori, Cytomegalovirus, or Herpes Simplex Virus Infection?” Stroke 31:9 (2000): 2127–2133.

  66. Jahromi, B.S., M.D. Hill, K. Holmes, et al. “Chlamydia pneumoniae and Atherosclerosis following Carotid Endarterectomy.” Can J Neurol Sci 30:4 (2003): 333–339.

  67. Subramanian, A.K., T.C. Quinn, T.S. Kickler, et al. “Correlation of Chlamydia pneumoniae Infection and Severity of Accelerated Graft Arteriosclerosis after Cardiac Transplantation.” Transplantation 73:5 (2002): 761–764.

  68. Kuo, C.C., J.T. Grayston, L.A. Campbell, et al. “Chlamydia Pneumoniae (TWAR) in Coronary Arteries of Young Adults (15–35 Years Old).” Proc Natl Acad Sci USA 92 (1995): 6911–6914.

  69. Ngeh, J., V. Anand, S. Gupta. “Chlamydia pneumoniae and Atherosclerosis—W
hat We Know and What We Don’t.” Clin Microbiol Infect 8:1 (2002): 2–13.

  70. Fong, I.W., B. Chiu, E. Viira, et al. “Rabbit Model for Chlamydia pneumoniae Infection.” J Clin Microbiol 35 (1997): 48–52. Laitinen, K., A. Laurila, L. Pyhala, et al. “Chlamydia pneumoniae Infection Induces Inflammatory Changes in the Aorta of Rabbits.” Infect Immun 65 (1997): 4832–4835. Moazed, T.C., L.A. Campbell, M.E. Rosenfeld, et al. “Chlamydia pneumoniae Infection Accelerates the Progression of Atherosclerosis in Apolipoprotein (Apo E)-Deficient Mice.” J Infect Dis 180 (1999): 238–241. Muhlestein, J.B., J.L. Anderson, E.H. Hammond, et al. “Infection with Chlamydia pneumoniae Accelerates the Development of Atherosclerosis and Treatment with Azithromycin Prevents It in a Rabbit Model.” Circulation 97:7 (1998): 633–636.

  71. Gurfinkel, E. “Link Between Intracellular Pathogens and Cardiovascular Diseases.” Clin Microbiol Infect 4:Suppl 4 (1998): S33-S36.

  72. Kalayoglu, M.V., B. Hoerneman, D. LaVerda, et al. “Cellular Oxidation of Low-Density Lipoprotein by Chlamydia pneumoniae.” J Infect Dis 180 (1999): 780–790.

  73. Shi, Y., and O. Tokunaga. “Herpesvirus (HSV-1, EBV and CMV) Infections in Atherosclerotic Compared with Non-atherosclerotic Aortic Tissue.” Pathol Intl 52:1 (2002): 31–39.

  74. Musiani, M., M.L. Zerbini, A. Muscari, et al. “Antibody Patterns against Cytomegalovirus and Epstein-Barr Virus in Human Atherosclerosis.” Microbiologica 13:1 (1990): 35–41.

  75. Tabib, A., C. Leroux, J.F. Mornex, et al. “Accelerated Coronary Atherosclerosis and Arteriosclerosis in Young Human-Immunodeficiency-Virus-Positive Patients.” Coron Artery Dis 11:1 (2000): 41–46.

  76. Rota, S. “Mycobacterium tuberculosis Complex in Atherosclerosis.” Acta Med Okayama 59:6 (2005): 247–251.

  77. Haraszthy, V.I., J.J. Zambon, M. Trevisan, et al. “Identification of Periodontal Pathogens in Atheromatous Plaques.” J Periodontol 71:10 (2000): 1554–1560.

  78. Fong, I.W. “Infections and Their Role in Atherosclerotic Vascular Disease.” J Am Dent Assoc 133:Suppl (2002): 7S–13S.

  79. Meurman, J.H., M. Sanz, S.J. Janket. “Oral Health, Atherosclerosis, and Cardiovascular Disease.” Crit Rev Oral Biol Med 15:6 (2004): 403–413.

  80. Suarna, C., R.T. Dean, J. May, et al. “Human Atherosclerotic Plaque Contains Both Oxidized Lipids and Relatively Large Amounts of Alpha-tocopherol and Ascorbate.” Arterioscler Thromb Vasc Biol 15:10 (1995): 1616–1624.

  81. Hickey, S., H.J. Roberts, and R.F. Cathcart. “Dynamic Flow.” J Orthomolecular Med 20:4 (2005): 237–244.

  82. O’Brien, K.D., C.E. Alpers, J.E. Hokanson, et al. “Oxidation-specific Epitopes in Human Coronary Atherosclerosis are Not Limited to Oxidized Low-density Lipoprotein.” Circulation 94:6 (1996): 1216–1225. Westhuyzen, J. “The Oxidation Hypothesis of Atherosclerosis: An Update.” Ann Clin Lab Sci 27:1 (1997): 1–10. Reaven, P.D., and J.L. Witztum. “Oxidized Low-density Lipoproteins in Atherogenesis: Role of Dietary Modification.” Annu Rev Nutr 16 (1996): 51–71. Meagher, E., and D.J. Rader. “Antioxidant Therapy and Atherosclerosis: Animal and Human Studies.” Trends Cardiovasc Med 11:3–4 (2001): 162–165.

  83. Cooke, J.P. “Is Atherosclerosis an Arginine Deficiency Disease?” J Investig Med 46 (1998): 377–380.

  84. Tapiero, H., G. Mathe, P. Couvreur, et al. “Arginine.” Biomed Pharmacother 56 (2002): 439–445. Preli, R.B., K.P. Klein, D.M. Herrington. “Vascular Effects of Dietary L-Arginine Supplementation.” Atherosclerosis 162 (2002): 1–15. Tiefenbacher, C.P. “Tetrahydrobiopterin: A Critical Cofactor for eNOS and a Strategy in the Treatment of Endothelial Dysfunction?” Am J Physiol Heart Circ Physiol 280 (2001): H2484–H2488.

  85. van Hinsbergh, V.W. “NO or H2O2 for Endothelium-dependent Vasorelaxation: Tetrahydrobiopterin Makes the Difference.” Arterioscler Thromb Vasc Biol 21 (2001): 719–721.

  86. Lehr, H.A., G. Germann, G.P. McGregor, et al. “Consensus Meeting on ’Relevance of Parenteral Vitamin C in Acute Endothelial-dependent Pathophysiological Conditions (EDPC)’.” Eur J Med Res 11:12 (2006): 516–526.

  87. Clementi, E., G.C. Brown, M. Feelisch. “Persistent Inhibition of Cell Respiration by Nitric Oxide: Crucial Role of S-Nitrosylation of Mitochondrial Complex 1 and Protective Action of Glutathione.” Proc Natl Acad Sci USA 95 (1998): 7631–7636. Mogi, M., K. Kinpara, A. Kondo, et al. “Involvement of Nitric Oxide and Biopterin in Proinflammatory Cytokine-induced Apoptotic Cell Death in Mouse Osteoblastic Cell Line MC3T3.” Biochem Pharmacol 58 (1999): 649–654. Bouton, C. “Nitrosative and Oxidative Modulation of Iron Regulatory Proteins.” Cell Mol Life Sci 55 (1999): 1043–1053. Donnini, S., and M. Ziche. “Constitutive and Inducible Nitric Oxide Synthase: Role in Angiogenesis.” Antioxid Redox Signal 4 (2002): 817–823.

  88. Anderson, T.J. “Assessment and Treatment of Endothelial Dysfunction in Humans.” J Am Coll Cardiol 34 (1999): 631–638. Watts, G.F., D.A. Playford, K.D. Croft, et al. “Coenzyme Q(10) Improves Endothelial Dysfunction of the Brachial Artery in Type II Diabetes Mellitus.” Diabetologia 45 (2002): 420–426.

  89. Cooke, J.P. “Does ADMA Cause Endothelial Dysfunction?” Arterioscler Thromb Vasc Biol 20 (2000): 2032–2037. Mukherjee, S., S.D. Coaxum, M. Maleque, et al. “Effects of Oxidized Low-density Lipoprotein on Nitric Oxide Synthetase and Protein Kinase C Activities in Bovine Endothelial Cells.” Cell Mol Biol 47 (2001): 1051–1058.

  90. Kirsch, M., H.G. Korth, R. Sustmann, et al. “The Pathobiochemistry Nitrogen Dioxide.” Biol Chem 383 (2002): 389–399. Chaudiere, J., and R. Ferrari-Iliou. “Intracellular Antioxidants: From Chemical to Biochemical Mechanisms.” Food Chem Toxicol 37 (1999): 949–962. Regoli, F., and G.W. Winston. “Quantification of Total Oxidant Scavenging Capacity of Antioxidants for Peroxynitrite, Peroxyl Radicals, and Hydroxyl Radicals.” Toxicol Appl Pharmacol 156 (1999): 96–105.

  91. Ceriello, A. “New Insights on Oxidative Stress and Diabetic Complications May Lead to a “Causal” Antioxidant Therapy.” Diabetes Care 26 (2003): 1589–1596. Trujillo, M., and R. Radi. “Peroxynitrite Reaction with the Reduced and the Oxidized Forms of Lipoic Acid: New Insights into the Reaction of Peroxynitrite with Thiols.” Arch Biochem Biophys 397 (2002): 91–98. Nakagawa, H., E. Sumiki, M. Takusagawa, et al. “Scavengers for Peroxynitrite: Inhibition of Tyrosine Nitration and Oxidation with Tryptamine Derivatives, Alpha-lipoic Acid and Synthetic Compounds.” Chem Pharm Bull 48 (2000): 261–265. Whiteman, M., H. Tritschler, B. Halliwell. “Protection against Peroxynitrite-dependent Tyrosine Nitration and Alpha-1-antiproteinase Inactivation by Oxidized and Reduced Lipoic Acid.” FEBS Lett 379 (1996): 74–76. Packer, L., K. Kraemer, G. Rimbach. “Molecular Aspects of Lipoic Acid in the Prevention of Diabetes Complications.” Nutrition 17 (2001): 888–895.

  92. Schopfer, F., N. Riobo, M.C. Carreras, et al. “Oxidation of Ubiquinol by Peroxynitrite: Implications for Protection of Mitochondria against Nitrosative Damage.” Biochem J 349 (2003): 35–42.

  93. Kjoller-Hansen, L., S. Boesgaard, J.B. Laursen, et al. “Importance of Thiols (SH Group) in the Cardiovascular System.” Ugeskr Laeger 155 (1993): 3642–3645. Ferrari, R., C. Ceconi, S. Curello, et al. “Oxygen Free Radicals and Myocardial Damage: Protective Role of Thiol-containing Agents.” Am J Med 91 (1991): 95S–105S. Cheung, P.Y., W. Wang, R. Schulz. “Glutathione Protects against Myocardial Ischemia-reperfusion Injury by Detoxifying Peroxynitrite.” J Mol Cell Cardiol 32 (2000): 1669–1678. Deneke, S.M. “Thiol-based Antioxidants.” Curr Top Cell Regul 36 (2000): 151–180. Del Corso, A., P.G. Vilardo, M. Cappiello, et al. “Physiological Thiols as Promoters of Glutathione Oxidation and Modifying Agents in Protein S Thiolation.” Arch Biochem Biophys 397 (2002): 392–398. Ramires, P.R., and L.L. Ji. “Glutathione Supplementation and Training Increases Myocardial Resistance to Ischemia-reperfusion in Vivo.” Am J Physiol Heart Circ Physiol 281 (2001): H679–H688.

  94. Chaudiere, J., and R. Ferrari-Iliou. “Intracellular Antioxidants: From Chemical to Biochemical Mechanisms.” Food Chem Toxicol 37 (1999): 949–962.

  95. McCarty, M.F. “Oxidants Downstream from Sup
eroxide Inhibit Nitric Oxide Production by Vascular Endothelium—A Key Role for Selenium-dependent Enzymes in Vascular Health.” Med Hypotheses 53 (1999): 315–325.

  96. Terao, J., S. Yamaguchi, M. Shirai, et al. “Protection by Quercetin and Quercetin 3-O-beta-D-glucuronide of Peroxynitrite-induced Antioxidant Consumption in Human Plasma Low-density Lipoprotein.” Free Radical Res 35 (2001): 925–931. Haenen, G.R., J.B. Paquay, R.E. Korthouwer, et al. “Peroxynitrite Scavenging by Flavonoids.” Biochem Biophys Res Commun 236 (1997): 591–593.

  97. Hickey, S., H.J. Roberts, R.F. Cathcart. “Dynamic Flow.” J Orthomolecular Med 20:4 (2005): 237–244.

  98. Simon, E., J. Gariepy, A. Cogny, et al. “Erythrocyte, but Not Plasma, Vitamin E Concentration is Associated with Carotid Intima-media Thickening in Asymptomatic Men at Risk for Cardiovascular Disease.” Atherosclerosis 159 (2001): 193–200. Andreeva-Gateva, P. “Antioxidant Vitamins—Significance for Preventing Cardiovascular Diseases. Part 1. Oxidized Low-density Lipoproteins and Atherosclerosis; Antioxidant Dietary Supplementation—Vitamin E.” Vutr Boles 32 (2000): 11–18. Bolton-Smith, C., M. Woodward, H. Tunstall-Pedoe. “The Scottish Heart Health Study. Dietary Intake by Food Frequency Questionnaire and Odds Ratios for Coronary Heart Disease Risk. II. The Antioxidant Vitamins and Fibre.” Eur J Clin Nutr 46 (1992): 85–93. Eichholzer, M., H.B. Stahelin, K.F. Gey. “Inverse Correlation between Essential Antioxidants in Plasma and Subsequent Risk to Develop Cancer, Ischemic Heart Disease and Stroke, Respectively: 12-Year Follow-up of the Prospective Basel Study.” EXS 62 (1992): 398–410. O’Byrne, D., S. Grundy, L. Packer, et al. “Studies of LDL Oxidation Following Alpha-, Gamma-, or Delta-tocotrienyl Acetate Supplementation of Hypercholesterolemic Humans.” Free Radical Biol Med 29 (2000): 834–845.